Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Carlos Alberto Gomez-Roca, Valentina Boni, Victor Moreno, John Charles Morris, Jean-Pierre Delord, Emiliano Calvo, Kyriakos P. Papadopoulos, Olivier Rixe, Patrick Cohen, Alexia Tellier, Samira Ziti-Ljajic, Anthony W. Tolcher | ||||||||||||
Title | A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/record/125293/abstract | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 2511) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR566658 | SAR-566658 | SAR566658 is a monoclonal antibody against CA6 in conjugation with maytansinoid, which may deliver targeted cytotoxicity to MUC-1 over expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 2511), PMID: 32451330). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|